文献速递神经肿瘤

Pin1介导的SUMO1修饰促进胶质瘤干细胞恶性表型

Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy.
PubMed 文献 · Neuro Oncol · 2020-01-01

该研究探讨胶质瘤干细胞(GSC)中蛋白SUMO化修饰的作用,发现SUMO1修饰(而非SUMO2/3)在GSC中高表达,PML为主要SUMO1底物,其修饰促进与c-Myc结合并稳定c-Myc蛋白。Pin1为关键调控酶,敲低Pin1或用抑制剂Juglone破坏SUMO1修饰可抑制GSC维持和肿瘤生长,提示靶向SUMO1修饰可能改善胶质母细胞瘤治疗。

要点

  • GSC中SUMO1修饰水平高,SUMO2/3修饰不明显。
  • PML是GSC中主要SUMO1底物,其修饰稳定c-Myc蛋白。
  • Pin1是促进SUMO1修饰的关键酶,抑制Pin1可削弱GSC致瘤性。

核心结论

  • 高SUMO1修饰的蛋白SUMO化是GSC的特征,对GSC维持至关重要,靶向SUMO1修饰可能有效改善GBM治疗。

研究设计与样本

  • 研究使用患者来源的GSC、原代GBM切片和颅内GBM异种移植模型,通过免疫印迹、定量PCR、免疫沉淀、免疫荧光和免疫组化检测蛋白SUMO化及相关分子机制。
  • 采用原位GBM异种移植模型,通过shRNA或分子抑制剂破坏蛋白SUMO化来研究肿瘤生长抑制。

主要发现

  • GSC中高水平的SUMO1修饰(而非SUMO2/3修饰)优先存在。
  • PML蛋白是GSC中主要的SUMO1修饰底物,其SUMO化促进与c-Myc相互作用并稳定c-Myc蛋白。
  • 脯氨酰异构酶Pin1在GSC中优先表达,作为关键酶促进SUMO1修饰。
  • 通过shRNA沉默Pin1或用抑制剂Juglone抑制Pin1,破坏SUMO1修饰,显著削弱GSC维持并减轻GSC驱动的肿瘤生长。

临床怎么用

  • 靶向Pin1或SUMO1修饰通路可能成为胶质母细胞瘤治疗的新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The tumorigenic potential of glioma stem cells (GSCs) is associated with multiple reversible molecular alternations, but the role of posttranslational protein sumoylation in GSCs has not been elucidated. The development of GSC-targeting drugs relies on the discovery of GSC-preferential molecular modifications and the relevant signaling pathways. In this work, we investigated the protein sumoylation status, the major sumoylated substrate, and the key regulatory enzyme in GSCs to explore the therapeutic potential of disrupting protein sumoylation for glioblastoma (GBM) treatment. METHODS: Patient-derived GSCs, primary GBM sections, and intracranial GBM xenografts were used to determine protein sumoylation and the related molecular mechanisms by immunoblot, quantitative PCR, immunoprecipitation, immunofluorescence, and immunohistochemistry. Orthotopic GBM xenograft models were applied to investigate the inhibition of tumor growth by disrupting protein sumoylation with short hairpin (sh)RNAs or molecular inhibitors. RESULTS: We show that high levels of small ubiquitin-related modifier 1 (SUMO1)-but not SUMO2/3-modified sumoylation are preferentially present in GSCs. The promyelocytic leukemia (PML) protein is a major SUMO1-sumoylated substrate in GSCs, whose sumoylation facilitates its interaction with c-Myc to stabilize c-Myc proteins. The prolyl-isomerase Pin1 is preferentially expressed in GSCs and functions as the key enzyme to promote SUMO1 sumoylation. Disruption of SUMO1 sumoylation by Pin1 silencing with shRNAs or inhibition with its inhibitor Juglone markedly abrogated GSC maintenance and mitigated GSC-driven tumor growth. CONCLUSIONS: Our findings indicate that high SUMO1-modified protein sumoylation as a feature of GSCs is critical for GSC maintenance, suggesting that targeting SUMO1 sumoylation may effectively improve GBM treatment.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Zhang A, Tao W, Zhai K, et al. Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy. Neuro Oncol. 2020. PMID: 32592588. doi:10.1093/neuonc/noaa150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。